Role of N6-Methyladenosine (m6A) Methylation Regulators in Hepatocellular Carcinoma

Liver cancer is the fifth most common malignant tumor in terms of incidence and the third leading cause of cancer-related mortality globally. Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Although great progress has been made in surgical techniques, hepatic artery chemoembolization, molecular targeting and immunotherapy, the prognosis of liver cancer patients remains very poor. N6-methyladenosine (m6A) is the most abundant internal RNA modification in eukaryotic cells and regulates various stages of the RNA life cycle. Many studies have reported that the abnormal expression of m6A-related regulators in HCC represent diagnostic and prognostic markers and potential therapeutic targets. In this review, firstly, we introduce the latest research on m6A-related regulators in detail. Next, we summarize the mechanism of each regulator in the pathogenesis and progression of HCC. Finally, we summarize the potential diagnostic, prognostic and therapeutic value of the regulators currently reported in HCC.

Analysis on the Clinical Therapeutic Effect of Hepatic Artery Chemoembolization in the Treatment of Advanced Liver Cancer

Objective: To study and analyze the clinical efficacy of gemcitabine combined with Tegafur chemotherapy after radical resection of pancreatic cancer. Methods: The subjects of the study were 200 patients who were admitted to the hospital from January 2018 to February 2021 requiring chemotherapy after radical resection of pancreatic cancer. According to the different treatment methods, they were divided into a experimental group (gemcitabine combined with Tegafur chemotherapy) and a control group (single gemcitabine chemotherapy), and the treatment efficacy of the two groups of patients was observed and compared. Results: Compared with the control group, patients in the experimental group had significantly better treatment efficacy, quality of life scores and post-treatment anxiety and depression scores. The difference between the groups was significant (p<0.05). Conclusion: Gemcitabine combined with Tegafur chemotherapy for patients requiring chemotherapy after radical resection of pancreatic cancer can significantly improve the treatment efficacy for the disease, improve the patient's quality of life, and ensure that the patient's emotional state during treatment is more positive.

Transarterial chemoembolisation in the treatment of patients with metastatic colorectal cancer

Aim. To assess effectiveness of chemoembolization of hepatic artery (CEHA) in treatment of patients with metastatic colorectal cancer, and also to determine the optimal interval in combination of CEHA with other treatment methods. Materials and Methods. The study includes analysis of the results of treatment of 30 patients with resectable metastases of colorectal cancer in the liver. The first group included 15 patients with resection made 1 week after CEHA. The second group consisted of 15 patients in whom resection operation was made 2 weeks after CENA with subsequent assessment of morphological changes in metastases. Results. Therapeutic pathomorphism was recorded in 25/30 patients. In the first group, therapeutic pathomorphism was observed in 13/15 patients. In 11/13 patients, the 2nd degree of therapeutic pathomorphism was recorded. In 2/13 patients – the 1st degree. In the second group, therapeutic pathomorphism was observed in 12/15 patients. In all patients the 2nd degree of therapeutic pathomorphism was recorded. No significant differences in the degree of therapeutic pathomorphism were recorded on the 7th and 14th day after regional chemotherapy (p=0.436). Conclusion. Hepatic artery chemoembolization is an effective method of treating patients with metastases of colorectal cancer in the liver. In use of chemoembolization of hepatic artery in combination with other surgical methods, the sevenday time interval is optimal.

Transarterial chemoembolisation in the treatment of patients with metastatic colorectal cancer

Aim. To assess effectiveness of chemoembolization of hepatic artery (CEHA) in treatment of patients with metastatic colorectal cancer, and also to determine the optimal interval in combination of CEHA with other treatment methods. Materials and Methods. The study includes analysis of the results of treatment of 30 patients with resectable metastases of colorectal cancer in the liver. The first group included 15 patients with resection made 1 week after CEHA. The second group consisted of 15 patients in whom resection operation was made 2 weeks after CENA with subsequent assessment of morphological changes in metastases. Results. Therapeutic pathomorphism was recorded in 25/30 patients. In the first group, therapeutic pathomorphism was observed in 13/15 patients. In 11/13 patients, the 2nd degree of therapeutic pathomorphism was recorded. In 2/13 patients – the 1st degree. In the second group, therapeutic pathomorphism was observed in 12/15 patients. In all patients the 2nd degree of therapeutic pathomorphism was recorded. No significant differences in the degree of therapeutic pathomorphism were recorded on the 7th and 14th day after regional chemotherapy (p=0.436). Conclusion. Hepatic artery chemoembolization is an effective method of treating patients with metastases of colorectal cancer in the liver. In use of chemoembolization of hepatic artery in combination with other surgical methods, the sevenday time interval is optimal.